A New Line Of Sight
Into Targeted Cancer Therapies

View List

Viewpoint CSO leads the DOE Lead-212 Users Meeting at SNMMI

Jun 22, 2019

June 22, 2019 | Anaheim, CA.

Viewpoint Co-Founder and Chief Science Officer Michael K. Schultz, PhD led the Department of Energy Lead-212 User Meeting at the 2019 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, held in Anaheim, CA. This event is a forum for the radiopharmaceutical community to come together and share respective success and challenges of introducing alpha-particle radionuclide therapy for cancer using lead-212. Dr. Schultz has consecutively led this event at the SNMMI annual meeting for the past three years.